<DOC>
	<DOCNO>NCT00002074</DOCNO>
	<brief_summary>To compare safety effectiveness fluconazole amphotericin B maintenance treatment prevent relapse cryptococcal meningitis patient AIDS .</brief_summary>
	<brief_title>Multicenter Comparison Fluconazole ( UK-49,858 ) Amphotericin B Maintenance Treatment Prevention Relapse Cryptococcal Meningitis Patients With Acquired Immunodeficiency Syndrome</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Cryptococcal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antivirals zidovudine . Prophylaxis ( include aerosolize pentamidine ) Pneumocystis carinii pneumonia ( PCP ) . Pfizer must notify patient receive ganciclovir ( DHPG ) entry . Concurrent Treatment : Allowed : Radiation therapy mucocutaneous Kaposi 's sarcoma . Patients must orient person , place , time , able give write informed consent . Patients must acute episode cryptococcal meningitis document recovery identification Cryptococcus neoformans lumbar cerebrospinal fluid ( CSF ) culture within 6 month prior entry . Minimum total dose 15 mg/kg amphotericin B must give ( either alone combination flucytosine ) primary therapy . Patients need receive amphotericin B time randomization must begin study maintenance therapy within 6 week completion primary amphotericin B therapy . Patients may receive maintenance amphotericin B period completion primary therapy study entry . Prior Medication : Allowed : Antivirals zidovudine ( AZT ) . Prophylaxis ( include aerosolize pentamidine ) Pneumocystis carinii pneumonia ( PCP ) . Exclusion Criteria Coexisting Condition : Patients follow exclude : Clinical evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease . Concurrent Medication : Excluded : Ketoconazole . Fluconazole . Itraconazole . Miconazole . Any systemic imidazole azole 7 day initiation primary therapy cryptococcosis . Intrathecal amphotericin B. Coumarintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Concurrent Treatment : Excluded : Lymphocyte replacement . Patients follow exclude : Clinical evidence acute chronic meningitis base upon etiology cryptococcosis . History allergy intolerance imidazole , azoles , amphotericin B . Moderate severe liver disease . Inability take oral medication reliably . Prior Medication : Excluded : Ketoconazole . Fluconazole . Itraconazole . Miconazole . Any systemic imidazole azole 7 day initiation primary therapy cryptococcosis . Intrathecal amphotericin B. Coumarintype anticoagulant . Oral hypoglycemics . Barbiturates . Phenytoin . Immunostimulants . Investigational drug approve ( license ) drug investigational indication . Any exception prohibition concomitant medication must approve Pfizer Central Research . Prior Treatment : Excluded : Lymphocyte replacement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1990</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Cryptococcosis</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Amphotericin B</keyword>
</DOC>